NCT06345703

First-into-human Study of NS-136 in Healthy Subjects

Name: Clinical Trial NCT06345703
Creator: NeuShen Therapeutics
Keywords: Healthy Subjects, Placebo, Phase 1, drug, clinical trial, Australia

A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects

NeuShen Therapeutics·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Healthy Subjects
Drug/Device/Intervention: Placebo
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: NeuShen Therapeutics
Location: Adelaide, Australia

Timeline & enrollment

Phase: Phase 1
Start date: Apr 30, 2024
End date: Feb 01, 2025
Enrollment: 60 participants

Primary outcome

Number of Participants with Treatment-Related Adverse Events,Main pharmacokinetic parameters,Main pharmacokinetic parameters,Main pharmacokinetic parameters,Main pharmacokinetic parameters,Main pharmacokinetic parameters,Main pharmacokinetic parameters

Summary

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are:  - Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen?  - What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?

ICD-10 classifications

Occupational health examinationSeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulRoutine child health examinationExamination and observation for other reasons

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06345703
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06345703 through Pure Global AI's free database. This Phase 1 trial is sponsored by NeuShen Therapeutics and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.